Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

FDG-PET appears promising for predicting prognosis of patients with inoperable NSCLC

06.10.2011
The prognosis for patients with stage II and III inoperable non-small cell lung cancer (NSCLC) is poor, with only about 15 percent of patients surviving at five years post-treatment for the disease.

While new treatment strategies are being intensely studied, timely assessment of their efficacy has proven difficult. In a presentation today, Mitchell Machtay, MD, principal investigator of the ACRIN 6668/RTOG 0235 trial and RTOG deputy chair, reported the that post-treatment F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) scans show promise for predicting the prognosis of patients with inoperable disease.

"These results are encouraging," says Machtay. "Definitive prognostic information after a patient completes therapy has not been available for making decisions about further treatment options, and these preliminary results suggest that FDG-PET may play an important role in that regard."

Twenty ACRIN and RTOG participating sites enrolled 251 patients into the phase III trial that gathered pre- and post-treatment FDG-PET scans — treatment included both chemotherapy and radiation therapy. Specifically, investigators sought to determine if the standardized uptake value (SUV), a quantitative measure of how rapidly tumor cells are using the glucose-based FDG radiotracer, obtained on post-treatment FDG-PET scans was predictive of a patient's survival. As Machtay reported, "The post-treatment scan was predictive for patients' prognosis by identifying that patients with high levels of FDG uptake following treatment had more aggressive tumors that were more likely to recur, and the higher the SUV measure in the primary tumor, the greater the recurrence rate and the lower a patient's corresponding survival outlook."

"The results announced today suggest that FDG-PET has a role in helping physicians make more informed treatment decisions, such as starting a patient on a new chemotherapy program," says Barry Siegel, MD, ACRIN co-deputy chair and medical director of the ACR PET Imaging Core Laboratory, "and helping investigators determine whether a treatment regimen is worthy of further study before long-term survival data are available."

The FDG-PET scan results provided for this analysis were interpreted by physicians at the participating sites. Further analyses are ongoing evaluating scan data interpreted by central review at the ACR Imaging Core Laboratory and using other semi-quantitative measures.

The study is supported by the NCI: ACRIN grants U01 CA 079778 and CA080098, and RTOG grants U10 CA21661 and CA37422.

For interviews with an ACRIN or RTOG investigator, please contact Heather Curry at 703-390-9822 or PR@acr.org.

ACRIN, a member of the NCI Clinical Trials Cooperative Group program, is made up of investigators from over 100 academic and community-based facilities in the United States and abroad. ACRIN's oncology mission is to develop information through clinical trials of medical imaging with the potential to increase the length and quality of life of cancer patients. As recently announced, the oncology research agendas of ACRIN and the Eastern Cooperative Oncology Group are soon to be merged, with biomarker research as a central focus. ACRIN also carries out research through its cardiovascular and neuroscience committees. Its imaging core laboratory supports the imaging operations of the ACRIN enterprise as well as other organizations carrying out imaging research. ACRIN is headquartered at the ACR Clinical Research Center in Philadelphia, PA. The ACRIN Biostatistics Center is located at Brown University in Providence, RI. www.acrin.org

The Radiation Therapy Oncology Group (RTOG) is administered by the American College of Radiology (ACR) and located in the ACR Center for Clinical Research in Philadelphia, PA. RTOG is a multi-institutional, international clinical cooperative group funded primarily by National Cancer Institute grants CA21661, CA32115 and CA37422. RTOG has 40 years of experience in conducting clinical trials and is comprised of over 300 major research institutions in the United States, Canada and internationally. The group currently is currently accruing to 40 studies that involve radiation therapy alone or in conjunction with surgery and/or chemotherapeutic drugs or which investigate quality of life issues and their effects on the cancer patient. The American College of Radiology (ACR) is a national professional organization serving more than 32,000 radiologists, radiation oncologists, interventional radiologists and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services.

Heather Curry | EurekAlert!
Further information:
http://www.acr.org
http://www.rtog.org

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>